Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News NightHawk Biosciences Inc. NHWK

NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has two categories: Oncology and Biodefense.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NYSEAM:NHWK)

Fundamentals Snapshot (NYSEAM:NHWK)

Current News (NYSEAM:NHWK)

NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services

GlobeNewswire June 13, 2022

NightHawk Biosciences Provides First Quarter 2022 Business Update

GlobeNewswire May 16, 2022

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

GlobeNewswire May 10, 2022

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today

GlobeNewswire May 3, 2022

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

GlobeNewswire April 27, 2022

Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics

GlobeNewswire April 20, 2022

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

GlobeNewswire April 19, 2022

REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments

GlobeNewswire April 18, 2022

Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

GlobeNewswire April 18, 2022

Opinion & Analysis (NYSEAM:NHWK)

No current opinion is available.

Bullboard Posts (NYSEAM:NHWK)

anyone else following HTBX ?

Anyone else got any insights into HTBX ? had a couple of run ups a year ago and 6 months ago, since then, it is just dithering around the...
ghayes - November 8, 2021

News release

Very good release out today:
TanzaniteMotherLode - August 13, 2020


I can smell some BARDA FUNDING incoming. Get ready for LIFTOFF!!!
Greenmind - May 19, 2020

Test being designed to provide point-of-care diagnosis
TanzaniteMotherLode - March 23, 2020

HTBX bucking the trend

This stock is a machine, going to benefit from the corona virus pandemic.  Will be back in the dollars in short order.
TanzaniteMotherLode - March 16, 2020

Another good yahoo post

Heat Biologics is not just a CV play. Even without that massive upside opportunity for shareholder value, the partnership with Bristol...
TanzaniteMotherLode - March 10, 2020